Q2 and H1 FY26 earnings call transcript filed
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Midcap 150 and 1.4 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anthem Biosciences posted H1 FY26 revenue of Rs. 1,090 Cr, EBITDA Rs. 480 Cr (margin 41.4 percent), and PAT Rs. 309 Cr. Net cash Rs. 993 Cr. Commercial molecules grew to 14 from 10 at IPO, with 6 late phase. Management guided margins to upper end of 36 to 37 percent range. Unit-IV greenfield CAPEX of Rs. 1,000 Cr planned to double capacity within two years.
Strong margin guidance and pipeline expansion reinforce growth visibility, though specialty ingredients dipped as capacity was diverted to busy CRDMO business.